Banka BioLoo Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
BANKA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.0 pts more than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Banka BioLoo Limited reported FY2025-26 standalone revenue from operations of Rs. 5,975.76 lakhs (up ~8.7% from Rs. 5,500.03 lakhs) and consolidated revenue of Rs. 5,709.24 lakhs (up ~5.4% from Rs. 5,417.35 lakhs). The company swung to profit with standalone PAT of Rs. 38.21 lakhs and consolidated PAT of Rs. 39.31 lakhs, compared to losses of Rs. 929.64 lakhs and Rs. 890.87 lakhs respectively in the prior year. The auditors issued an unmodified (clean) opinion. Key concerns include Rs. 687.44 lakhs (25% of trade receivables) receivable from government bodies with Rs. 125.26 lakhs outstanding over two years with no provisioning. Enzotech Solutions Pvt Ltd, a wholly-owned subsidiary, has filed for Corporate Insolvency Resolution Process under IBC. Exceptional items include Rs. 29.52 lakhs (labour code impact) and Rs. 719.65 lakhs provision for subsidiary investment (standalone). Cash position improved to Rs. 1,021.18 lakhs (consolidated).
The company achieved a turnaround from heavy losses to modest profitability, indicating operational improvement. However, the subsidiary's insolvency proceedings and large outstanding government receivables without provisioning present material risks. Investors should monitor the resolution of Enzotech's CIRP and collection of aged receivables.